Company intelligence
AQEMIA
Scale drug discovery with quantum-inspired physics and generative AI
About AQEMIA
AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data. We are building a rapidly expanding portfolio of proprietary programs, alongside collaborations with top pharmaceutical companies. Multiple discovery successes are already achieved, with lead programs progressing through in vivo optimization. AQEMIA is part of the French Tech 120 program, which supports the most promising scale-ups in France with global impact potential. AQEMIA is member of the BioIndustry Association (BIA) and the Knowledge Quarter in London. AQEMIA is based in Paris (HQ) and London. We are growing and hiring! Discover our opportunities here: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA: https://www.welcometothejungle.com/fr/companies/aqemia
Verified activity
Signals from AQEMIA
2 published signals
Presence & Recognition
AQEMIA co-founder and CEO Maximilien Levesque tells the story of how Aqemia began, what our quantum-inspired AI changes in molecule discovery, and where we stand today in the first episode of Parole d'Entrepreneur, France Biotech's new series.
Reported by AQEMIA
People
AQEMIA welcomed Tanguy Masgnaux as Chief of Staff to the CEO.
Reported by Tanguy Masgnaux